Drug Approval | December 28, 2021
Strides to market molnupiravir under the brand name Stripiravir
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
The Home Healthcare market is expected to be US $ 14.2 by 2025
Sucharita brings with her a rich and varied experience of two decades in Information Technology and Financial Services
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
The hospital has recently launched Radionuclide therapy
He has over 22 years of experience in pharmaceutical sales & business development
Autism spectrum disorder affects 78 million people and families worldwide
Patient with acute Covid-19 infection treated at BGS Gleneagles Global Hospital
Subscribe To Our Newsletter & Stay Updated
